Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

Adjuvant Therapies for Dysembryoplastic Neuroepithelial Tumors in Children

This page was last updated on January 25th, 2023


  • Seizure medication: Antiepileptic medication can sometimes be gradually withdrawn in consultation with an epileptologist.
  • No chemotherapy: Chemotherapy is not used to treat these tumors.


  • Not indicated after complete resection: A general consensus exists that radiotherapy is not needed after surgical resection. The risk of recurrence after complete or subtotal resection is small. There is no proven benefit for adjuvant therapy, and the short- and long-term toxicities must be considered in these patients with a very long life expectancy. Similarly, there is no evidence for management with biopsy and radiotherapy in lesions in eloquent brain regions. Radiation has even been suspected to play a role in the rare cases of malignant transformation (31, 35).
  • Some use after surgery for recurrence: In cases of recurrence, radiotherapy after second surgery is advocated by some authors but is of unproven benefit.


  • Not used: There are no data on immunotherapy for DNETs.

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.